[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-335470-en":59,"doc-seo-335470-105":80},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":72,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":46,"preview_page_count":4},335470,2336464648746,"Skyler","https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","The Effects of Nebivolol-Gefitinib-Loratadine Against Lung Cancer Cell Lines","Non-small-cell lung cancer (NSCLC) is the most frequently diagnosed malignancy and a leading cause of cancer-related death, driving the need for more effective therapeutic options. Drug repurposing can provide simplified, affordable alternatives, and prior evidence suggests antihistamines and beta-blockers may inhibit cancer cell proliferation. This study investigates whether combining the antihistamine loratadine, the beta-blocker nebivolol, and the tyrosine-kinase inhibitor gefitinib can exert antineoplastic effects in A-549 and NCI-H1975 cell lines. Metabolic activity, apoptosis, and survival were assessed, showing a synergistic inhibitory effect and enhanced apoptosis.","in vivo 38: 2688-2695 (2024)  \ndoi:10.21873/invivo.13746  \nThe Effects of Nebivolol-Gefitinib-Loratadine Against Lung Cancer Cell Lines  \nJOSÉ LUIS MARTÍNEZ-LIRA 1,2 , ELISABETH HERNÁNDEZ-GALLEGOS 1 , MARÍA DE GUADALUPE CHÁVEZ-LÓPEZ1 , RICARDO VILLALOBOS-VALENCIA3 and JAVIER CAMACHO 1  \n1Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav-IPN), Ciudad de México, México;  \n2 UMAE, Hospital de Especialidades Νο . 25, Instituto Mexicano del Seguro Social, Monterrey Nuevo León, México;  \n3Departamento de Oncología Médica, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México  \nAbstract. Background/Aim: Non-small-cell lung cancer (NSCLC) is the most frequently diagnosed malignancy and the first cause of cancer-related death. Thus, finding alternative therapeutic options is crucial. Drug repurposing offers therapeutic options in a simplified and affordable manner, especially to cancer patients in developing countries. Several drugs including antihistamines and betaadrenergic receptor blockers (beta-blockers) display antiproliferative properties on cancer cells. Interestingly, NSCLC patients who had used either antihistamines or betablockers showed improved response to chemotherapy or reduced mortality in comparison to non-users of any of these drugs. However, combination therapy is gaining substantial interest in many cancers including non-EGFR mutated NSCLC. Here, we investigated the antineoplastic effect of the combination of the antihistamine loratadine, the beta-blocker nebivolol, and the tyrosine-kinase inhibitor gefitinib on NSCLC cell lines. Materials and Methods: A-549 and NCIH1975 cell lines were used. The effect of nebivolol, gefitinib,  \nCorrespondence to: Dr. Javier Camacho, Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav-IPN), Av. Instituto Politécnico Nacional 2508, CP 07360, Ciudad de México, México. Tel: +52 5557473800 ext. 5416, e-mail: [fcamacho@cinvestav.mx](fcamacho@cinvestav.mx)  \n[Key Words:](Key Words: Nebivolol)[ Nebivolol](Key Words: Nebivolol) , [loratadine](loratadine) , [non-small-cell lung cancer](non-small-cell lung cancer), [drug](drug)[ ](drug)[combination](combination) , [drug](drug) repurposing.  \n©2024 The Author(s) . Published by the International Institute of Anticancer Research.  \nThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license ([https://creativecommons.org/licenses/by-nc-nd/4.0](https://creativecommons.org/licenses/by-nc-nd/4.0)).  \nand loratadine on the metabolic activity was studied using the MTT assay. The inhibitory concentrations (IC20 and IC50) were calculated and used in the drug-combination experiments. Apoptosis was investigated using flow cytometry; and cell survival using the colony formation assay. Results: The combination nebivolol-loratadinegefitinib produced a significant synergistic effect on inhibiting the metabolic activity and colony formation, as well as on promoting apoptosis in both cell lines. Noteworthy, the effect on the cell line carrying the EGFR mutation (NCI-H1975) was very similar to the cell line that does not exhibit such mutation (A-549 cells) . Conclusion: The nebivolol-gefitinib-loratadine combination may be a promising alternative for lung cancer treatment.  \nLung cancer is the leading cause of cancer-related deaths worldwide (1). Non-small cell lung cancer (NSCLC), accounts for approximately 80% of all lung cancer cases and is the subtype in which oncogenic mutations are most relevant (2, 3) . The clinical treatment for NSCLC patients includes monoclonal antibodies, chemotherapeutic agents, and molecular targeted therapy (3-10) . However, these therapies usually become ineffective after a relatively short period of time, in most cases due t","cbCainwLM836pv5b","https://ap.wps.com/l/cbCainwLM836pv5b","pdf",3982260,16,"English","en",105,"# Abstract\n## Background/Aim\n## Materials and Methods\n## Results and Conclusion","[{\"question\":\"Why is drug repurposing considered important for NSCLC therapy?\",\"answer\":\"It offers therapeutic options in a simplified and more affordable manner. It can also provide reduced toxicity and a lower probability of resistance compared with some conventional approaches.\"},{\"question\":\"Which drugs were tested in combination in this study?\",\"answer\":\"The study evaluated a three-drug combination: loratadine, nebivolol, and gefitinib, administered against NSCLC cell lines.\"},{\"question\":\"What were the key findings of the nebivolol-loratadine-gefitinib combination?\",\"answer\":\"The combination produced a significant synergistic effect in inhibiting metabolic activity and colony formation. It also promoted apoptosis in both A-549 and NCI-H1975 cell lines.\"}]","The Effects of Nebivolol-Gefitinib-Loratadine Against Lung Cancer Cell Lines | PDF",1790011085,{"code":4,"msg":81,"data":82},"ok",{"site_id":75,"language":74,"slug":83,"title":65,"keywords":84,"description":66,"schema_data":85,"social_meta":139,"head_meta":141,"extra_data":143,"updated_unix":144},"the-effects-of-nebivolol-gefitinib-loratadine-against-lung-cancer-cell-lines","",{"@graph":86,"@context":138},[87,101,121],{"@type":88,"itemListElement":89},"BreadcrumbList",[90,94,96,99],{"item":91,"name":92,"@type":93,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":95,"name":9,"@type":93,"position":14},"https://docshare.wps.com/document/",{"item":97,"name":40,"@type":93,"position":98},"https://docshare.wps.com/document/research-report/",3,{"item":100,"name":65,"@type":93,"position":19},"https://docshare.wps.com/document/the-effects-of-nebivolol-gefitinib-loratadine-against-lung-cancer-cell-lines/335470/",{"url":100,"name":65,"@type":102,"image":103,"author":108,"headline":65,"publisher":110,"fileFormat":113,"inLanguage":74,"description":66,"dateModified":114,"datePublished":115,"encodingFormat":113,"isAccessibleForFree":116,"interactionStatistic":117},"DigitalDocument",{"url":104,"@type":105,"width":106,"height":107},"https://docshare.wps.com/thumbnails/the-effects-of-nebivolol-gefitinib-loratadine-against-lung-cancer-cell-lines/335470.png","ImageObject",300,407,{"name":63,"@type":109},"Person",{"url":91,"name":111,"@type":112},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":118,"interactionType":119,"userInteractionCount":72},"InteractionCounter",{"@type":120},"ViewAction",{"@type":122,"mainEntity":123},"FAQPage",[124,130,134],{"name":125,"@type":126,"acceptedAnswer":127},"Why is drug repurposing considered important for NSCLC therapy?","Question",{"text":128,"@type":129},"It offers therapeutic options in a simplified and more affordable manner. It can also provide reduced toxicity and a lower probability of resistance compared with some conventional approaches.","Answer",{"name":131,"@type":126,"acceptedAnswer":132},"Which drugs were tested in combination in this study?",{"text":133,"@type":129},"The study evaluated a three-drug combination: loratadine, nebivolol, and gefitinib, administered against NSCLC cell lines.",{"name":135,"@type":126,"acceptedAnswer":136},"What were the key findings of the nebivolol-loratadine-gefitinib combination?",{"text":137,"@type":129},"The combination produced a significant synergistic effect in inhibiting metabolic activity and colony formation. It also promoted apoptosis in both A-549 and NCI-H1975 cell lines.","https://schema.org",{"og:url":100,"og:type":140,"og:title":65,"og:site_name":111,"og:description":66},"article",{"robots":142,"canonical":100},"index,follow",{"doc_id":61,"site_id":75},1790172882]